INDV
insider transactionsIndivior Pharmaceuticals, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Cluster buy signal: Multiple insiders at the same company buying around the same time — often a stronger signal than a single buy. 6 different insiders made open-market purchases in the last 365 days, totalling $203.6K.
Net shares · 365d
-48.7K
5.8K buy · 54.6K sell
Net value · 365d
-$1.9M
$203.6K in · $2.1M out
Sentiment · 365d
Net selling
9% buying · 91% selling
Open-market trades · 365d
10
5.8K buy · 54.6K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
Chief Scientific Officer · 10b5-1
$707.4K
18.6K sh · $38.06
Own -8%
-
Sell·S
Ryan Preblick KEY
Chief Financial Officer · 10b5-1
$1.4M
36.0K sh · $37.70
Own -11%
-
Grant·A
Director
$0
6.5K sh
Own +114%
-
Grant·A
Director
$0
10.4K sh
Own +51%
-
Grant·A
Director
$0
6.5K sh
Own +101%
-
Grant·A
Director
$0
6.5K sh
Own +32%
-
Grant·A
Director
$0
6.5K sh
Own +117%
-
Grant·A
Director
$0
6.5K sh
Own +32%
-
Grant·A
Director
$0
6.5K sh
Own +68%
-
Other·F
Director
$42.8K
1.1K sh · $38.28
Own -15%
-
Exercise·M
Ryan Preblick KEY
Chief Financial Officer
—
6.3K sh
Own New
-
Other·F
Ryan Preblick KEY
Chief Financial Officer
$88.4K
2.8K sh · $31.11
Own -1%
-
Exercise·M
Ryan Preblick KEY
Chief Financial Officer
—
6.3K sh
Own +2%
-
Buy·P
Director
$249
8 sh · $31.09
Own +0%
-
Buy·P
Director
$1.0K
31 sh · $32.56
Own +1%
-
Buy·P
Director
$30.0K
940 sh · $31.87
Own +20%
-
Exercise·M
Ryan Preblick KEY
Chief Financial Officer
—
113.5K sh
Own New
-
Exercise·M
Ryan Preblick KEY
Chief Financial Officer
—
86.9K sh
Own +38%
-
Other·F
Ryan Preblick KEY
Chief Financial Officer
$2.8M
87.6K sh · $31.98
Own -28%
-
Exercise·M
Chief Scientific Officer
—
132.6K sh
Own New
-
Other·F
Chief Scientific Officer
$1.5M
45.8K sh · $31.98
Own -16%
-
Exercise·M
Chief Scientific Officer
—
101.5K sh
Own +53%
-
Exercise·M
Chief Legal Officer
—
104.3K sh
Own New
-
Other·F
Chief Legal Officer
$1.2M
36.0K sh · $31.98
Own -34%
-
Exercise·M
Chief Legal Officer
—
79.9K sh
Own +289%
-
Exercise·M
Chief Accounting Officer
—
5.9K sh
Own New
-
Exercise·M
Chief Accounting Officer
—
24.0K sh
Own New
-
Other·F
Chief Accounting Officer
$85.8K
2.7K sh · $31.98
Own -10%
-
Exercise·M
Chief Accounting Officer
—
5.9K sh
Own +28%
-
Other·F
Chief Accounting Officer
$264.9K
8.3K sh · $31.98
Own -28%
-
Exercise·M
Chief Accounting Officer
—
18.4K sh
Own +163%
-
Grant·A
Ryan Preblick KEY
Chief Financial Officer
$0
37.4K sh
Own +13%
-
Grant·A
Chief Scientific Officer
$0
33.6K sh
Own +21%
-
Grant·A
Joseph Ciaffoni KEY
Chief Executive Officer
$0
80.0K sh
Own +143%
-
Grant·A
Chief Legal Officer
$0
26.9K sh
Own +3539%
-
Grant·A
Chief Commercial Officer
$0
31.4K sh
Own New
-
Grant·A
Chief Accounting Officer
$0
6.9K sh
Own +157%
-
Grant·A
Ryan Preblick KEY
Chief Financial Officer
$0
113.5K sh
Own New
-
Grant·A
Chief Scientific Officer
$0
132.6K sh
Own New
-
Grant·A
Chief Legal Officer
$0
104.3K sh
Own New
-
Grant·A
Chief Accounting Officer
$0
24.0K sh
Own New
-
Grant·A
Director
$0
3.7K sh
Own +190%
-
Grant·A
Director
$0
6.0K sh
Own +41%
-
Grant·A
Director
$0
3.7K sh
Own +97%
-
Grant·A
Director
$0
3.7K sh
Own +22%
-
Grant·A
Director
$0
3.7K sh
Own +405%
-
Grant·A
Director
$0
3.7K sh
Own +22%
-
Grant·A
Director
$0
3.7K sh
Own +64%
-
Buy·P
Director · 10b5-1
$27.4K
775 sh · $35.39
Own +65%
-
Buy·P
Director · 10b5-1
$62.7K
1.8K sh · $35.39
Own +14%
-
Buy·P
Director · 10b5-1
$27.4K
775 sh · $35.39
Own +5%
-
Buy·P
Director · 10b5-1
$27.4K
775 sh · $35.39
Own +5%
-
Buy·P
Director · 10b5-1
$27.4K
775 sh · $35.39
Own +15%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 11, 2026 | Christian Heidbreder 10b5-1 | Sell S | 18.6K | $707.4K |
| Jun 8, 2026 | Ryan Preblick KEY 10b5-1 | Sell S | 36.0K | $1.4M |
| May 13, 2026 | Barbara Ryan | Grant A | 6.5K | $0 |
| May 13, 2026 | David E. Wheadon | Grant A | 10.4K | $0 |
| May 13, 2026 | Juliet Thompson | Grant A | 6.5K | $0 |
| May 13, 2026 | Mark Stejbach | Grant A | 6.5K | $0 |
| May 13, 2026 | Stuart A Kingsley | Grant A | 6.5K | $0 |
| May 13, 2026 | Daniel A Ninivaggi | Grant A | 6.5K | $0 |
| May 13, 2026 | Keith Humphreys | Grant A | 6.5K | $0 |
| May 12, 2026 | Juliet Thompson | Other F | 1.1K | $42.8K |
| Mar 14, 2026 | Ryan Preblick KEY | Exercise M | 6.3K | — |
| Mar 14, 2026 | Ryan Preblick KEY | Other F | 2.8K | $88.4K |
| Mar 14, 2026 | Ryan Preblick KEY | Exercise M | 6.3K | — |
| Mar 13, 2026 | Barbara Ryan | Buy P | 8 | $249 |
| Mar 9, 2026 | Barbara Ryan | Buy P | 31 | $1.0K |
| Mar 6, 2026 | Stuart A Kingsley | Buy P | 940 | $30.0K |
| Mar 3, 2026 | Ryan Preblick KEY | Exercise M | 113.5K | — |
| Mar 3, 2026 | Ryan Preblick KEY | Exercise M | 86.9K | — |
| Mar 3, 2026 | Ryan Preblick KEY | Other F | 87.6K | $2.8M |
| Mar 3, 2026 | Christian Heidbreder | Exercise M | 132.6K | — |
| Mar 3, 2026 | Christian Heidbreder | Other F | 45.8K | $1.5M |
| Mar 3, 2026 | Christian Heidbreder | Exercise M | 101.5K | — |
| Mar 3, 2026 | Jeffrey W Burris | Exercise M | 104.3K | — |
| Mar 3, 2026 | Jeffrey W Burris | Other F | 36.0K | $1.2M |
| Mar 3, 2026 | Jeffrey W Burris | Exercise M | 79.9K | — |
| Mar 3, 2026 | Woodrow D Anderson | Exercise M | 5.9K | — |
| Mar 3, 2026 | Woodrow D Anderson | Exercise M | 24.0K | — |
| Mar 3, 2026 | Woodrow D Anderson | Other F | 2.7K | $85.8K |
| Mar 3, 2026 | Woodrow D Anderson | Exercise M | 5.9K | — |
| Mar 3, 2026 | Woodrow D Anderson | Other F | 8.3K | $264.9K |
| Mar 3, 2026 | Woodrow D Anderson | Exercise M | 18.4K | — |
| Feb 10, 2026 | Ryan Preblick KEY | Grant A | 37.4K | $0 |
| Feb 10, 2026 | Christian Heidbreder | Grant A | 33.6K | $0 |
| Feb 10, 2026 | Joseph Ciaffoni KEY | Grant A | 80.0K | $0 |
| Feb 10, 2026 | Jeffrey W Burris | Grant A | 26.9K | $0 |
| Feb 10, 2026 | Patrick A Barry | Grant A | 31.4K | $0 |
| Feb 10, 2026 | Woodrow D Anderson | Grant A | 6.9K | $0 |
| Feb 9, 2026 | Ryan Preblick KEY | Grant A | 113.5K | $0 |
| Feb 9, 2026 | Christian Heidbreder | Grant A | 132.6K | $0 |
| Feb 9, 2026 | Jeffrey W Burris | Grant A | 104.3K | $0 |
| Feb 9, 2026 | Woodrow D Anderson | Grant A | 24.0K | $0 |
| Jan 26, 2026 | Barbara Ryan | Grant A | 3.7K | $0 |
| Jan 26, 2026 | David E. Wheadon | Grant A | 6.0K | $0 |
| Jan 26, 2026 | Juliet Thompson | Grant A | 3.7K | $0 |
| Jan 26, 2026 | Mark Stejbach | Grant A | 3.7K | $0 |
| Jan 26, 2026 | Stuart A Kingsley | Grant A | 3.7K | $0 |
| Jan 26, 2026 | Daniel A Ninivaggi | Grant A | 3.7K | $0 |
| Jan 26, 2026 | Keith Humphreys | Grant A | 3.7K | $0 |
| Jan 5, 2026 | Barbara Ryan 10b5-1 | Buy P | 775 | $27.4K |
| Jan 5, 2026 | David E. Wheadon 10b5-1 | Buy P | 1.8K | $62.7K |
| Jan 5, 2026 | Mark Stejbach 10b5-1 | Buy P | 775 | $27.4K |
| Jan 5, 2026 | Daniel A Ninivaggi 10b5-1 | Buy P | 775 | $27.4K |
| Jan 5, 2026 | Keith Humphreys 10b5-1 | Buy P | 775 | $27.4K |
About INDV insider trading
This page tracks insider transactions for Indivior Pharmaceuticals, Inc. (INDV) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.